お知らせ • Jun 25
Cryoport Systems Integricell Cryopreservation Services Selected by Verismo Therapeutics to Support Clinical Kir-Car T Cell Therapy Programs Cryoport Systems' IntegriCell cryopreservation services have been selected by Verismo Therapeutics, a clinical-stage CAR T cell therapy company pioneering a novel multi-chain KIR-CAR platform technology for the treatment of solid tumors (SynKIR-110) and B cell associated disorders and malignancies (SynKIR-310). Both candidates are in human clinical trials with initial Phase 1 data presented at the American Association for Cancer Research (AACR) 2026 Annual Meeting. IntegriCell cryopreservation services are designed to support cell and gene therapy programs throughout clinical development and into commercialization. By providing standardized manufacture-ready cryopreserved leukapheresis starting material within a globally standardized, GMP-compliant quality management system, IntegriCell enables developers to reduce variability, improve manufacturing efficiency and derisk their supply chains while delivering the scalable, reproducible solutions required to support global growth. IntegriCell will support cryopreservation for Verismo's two lead clinical programs: SynKIR-110, currently being evaluated in the STAR-101 Phase 1 trial in patients with advanced mesothelin-expressing solid tumors, and SynKIR-310, currently being evaluated in the CELESTIAL-301 Phase 1 trial in patients with relapsed or refractory B-cell non-Hodgkin lymphomas. Cryopreservation is an important component of the manufacturing process, and having a partner with the expertise to work within our existing workflow is essential. The IntegriCell team implemented our process with precision and worked alongside us to identify opportunities to improve process control and long-term scalability. These improvements position us well as we continue progressing toward future clinical and regulatory milestones to support our novel KIR-CAR platform. IntegriCell's cryopreservation service centers are strategically located in Houston, Texas and Liège, Belgium, providing geographic coverage to support clinical and commercial programs across the Americas and Europe. IntegriCell's capabilities integrate seamlessly with Cryoport Systems' broader temperature-controlled supply chain platform, spanning biologistics, biostorage and informatics, enabling clients to manage critical materials through a single partner relationship. Cryoport Systems further supports the availability of high-quality allogeneic starting materials through its strategic alliance with Gulf Coast Regional Blood Center, combining donor recruitment and apheresis collection expertise with IntegriCell's cryopreservation capabilities and Cryoport's Cryoshuttle temperature-controlled transport service. Verismo Therapeutics, a subsidiary of HLB Innovation, is a pioneer in multi-chain KIR-CAR technology, with assets SynKIR-110 (NCT05568680) and SynKIR-310 (NCT06544265) currently in Phase 1 clinical trials. Verismo is the only company developing the KIR-CAR platform, using a modified NK cell-derived receptor and DAP12 pairing, designed to improve T cell functional persistence and reduce exhaustion, resulting in improved efficacy against challenging tumors. The KIR-CAR platform technology was developed specifically to address areas of high unmet medical need, including advanced solid tumors and B cell associated disorders and malignancies. Recent Insider Transactions • Jun 09
Senior VP recently sold €2.4m worth of stock On the 4th of June, Robert Stefanovich sold around 169k shares on-market at roughly €14.00 per share. This transaction amounted to 61% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Robert has been a net seller over the last 12 months, reducing personal holdings by €2.4m. Buy Or Sell Opportunity • May 21
Now 28% overvalued after recent price rise Over the last 90 days, the stock has risen 65% to €11.90. The fair value is estimated to be €9.33, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has declined by 13% over the last 3 years. Earnings per share has grown by 7.6%. For the next 3 years, revenue is forecast to grow by 9.2% per annum. Earnings are also forecast to grow by 14% per annum over the same time period. Board Change • May 20
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 6 highly experienced directors. Independent Director Linda Baddour was the last director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment. お知らせ • May 06
Cryoport, Inc. Raises Revenue Guidance for the Full-Year 2026 Cryoport, Inc. raised revenue guidance for the full-year 2026. For the year, the company raised revenue guidance to $192 million to $196 million. お知らせ • Apr 23
Cryoport, Inc., Annual General Meeting, Jun 05, 2026 Cryoport, Inc., Annual General Meeting, Jun 05, 2026. お知らせ • Apr 21
Cryoport, Inc. to Report Q1, 2026 Results on May 04, 2026 Cryoport, Inc. announced that they will report Q1, 2026 results After-Market on May 04, 2026 お知らせ • Mar 04
Cryoport, Inc. Provides Revenue Guidance for the Full-Year 2026 Cryoport, Inc. provided revenue guidance for the full-year 2026. The Company provided full-year 2026 revenue guidance in the range of $190.0 million to $194.0 million. The Company's 2026 guidance is dependent on its current business and expectations, which may be impacted by, among other things, factors that are outside of control, such as national economic factors, the global macroeconomic and geopolitical environment, supply chain constraints, inflationary pressures, any U.S. federal government shutdown, tariffs and other trade restrictions and/or the effects of foreign currency fluctuations, as well as the other factors described in the Company's filings with the Securities and Exchange Commission (SEC), including in the "Risk Factors" section of its most recently filed periodic reports on Form 10-K and Form 10-Q, as well as in its subsequent filings with the SEC. お知らせ • Feb 17
Cryoport, Inc. to Report Q4, 2025 Results on Mar 03, 2026 Cryoport, Inc. announced that they will report Q4, 2025 results at 4:05 PM, US Eastern Standard Time on Mar 03, 2026 お知らせ • Feb 11
Cryoport's MVE Biological Solutions Introduces New Fusion 800 Series Cryoport, Inc. announced the launch of the MVE Fusion 800 Series, the next evolution of MVE Biological Solutions' patented, award-winning Fusion technology. This self-sustaining cryogenic freezer eliminates the need for a continuous liquid nitrogen (LN2) supply, delivering exceptional reliability, safety, and sustainability in a compact footprint designed for space-constrained environments. Recognized with the ISBER Outstanding New Product Award, MVE's Fusion technology transforms cryogenic storage. The new Fusion 800 builds on this innovative platform, offering the same trusted erformance and energy efficiency in a lab-sized design. At just 32 inches wide, it fits through standard doorways for easy installation without costly acility modifications. Ideal for medical research facilities, clinical development operations, hospital pharmacies and clinics, biorepositories, and blood and tissue banks, etc., the Fusion 800 offers versatile storage options for vials, blood bags, cassettes, etc., maintaining steady state temperatures at or below -150°C. お知らせ • Nov 05
Cryoport, Inc. Updates Revenue Guidance for the Fiscal Year 2025 Cryoport, Inc. updated revenue guidance for the fiscal year 2025. With momentum and year-to-date performance along with strong Third Quarter results, the company raising full-year revenue guidance from continuing operations to a range of $170.0 million to $174.0 million. お知らせ • Oct 21
Cryoport, Inc. to Report Q3, 2025 Results on Nov 04, 2025 Cryoport, Inc. announced that they will report Q3, 2025 results at 4:05 PM, US Eastern Standard Time on Nov 04, 2025 お知らせ • Oct 07
Cryoport, Inc. Introduces Real-Time Integrated Condition Monitoring Systems for Cryogenic Dewars Cryoport, Inc. announced the unveiling of MVE Biological Solutions integrated Condition Monitoring Solutions for its MVE SC 4/2 V and 4/3 V series dewars, both powered by Tec4Med, another Cryoport company. This launch reflects MVE's commitment to support the life sciences with intelligent, connected assets to safeguard vital commodities. Combining MVE's trusted cryogenic systems with advanced condition monitoring technology, the new monitoring and visibility systems integrate either a SmartTagTM or CryoBeaconTM, built directly into dewar lids, to provide centralized condition monitoring. All collected data is managed within the MVECloudTM, a secure web- and mobile-based FDA 21 CFR Part 11, GAMP 5 compliant platform that provides visibility, real time alerts, and reporting on the cryogenic environment in which commodities are stored. The CryoBeacon is a long-range Bluetooth Low Energy (BLE) 5.0 device that logs internal temperatures as low as -200degC, along with ambient temperature and humidity. Users can instantly retrieve data by scanning a QR code, making it easy to monitor both shipments and stationary storage equipment. The MVE SmartTag is a real-time condition-monitoring device with Long Term Evolution (LTE) connectivity and up to 120 days of battery life. It provides continuous visibility and alerts during transport or storage. お知らせ • Aug 13
Cryoport, Inc. announced delayed 10-Q filing On 08/12/2025, Cryoport, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC. お知らせ • Aug 06
Cryoport, Inc. Reiterates Revenue Guidance for Full Year Fiscal 2025 Cryoport, Inc. reiterated revenue guidance for full year fiscal 2025. For the period, the company is reiterating its revenue guidance for fiscal year 2025: total revenue from continuing operations is expected to be in the range of $165.0 million to $172.0 million, representing 5% to 10% growth year-over-year. The Company's 2025 guidance is dependent on its current business and expectations, which may be further impacted by, among other things, factors that are outside of the control, such as national economic factors, the global macroeconomic and geopolitical environment, supply chain constraints, inflationary pressures, tariffs and other trade restrictions and/or the effects of foreign currency fluctuations, as well as the other factors described in the Company's filings with the Securities and Exchange Commission ("SEC"), including in the "Risk Factors" section of its most recently filed periodic reports on Form 10-K and Form 10-Q, as well as in its subsequent filings with the SEC. お知らせ • Jul 22
Cryoport, Inc. to Report Q2, 2025 Results on Aug 05, 2025 Cryoport, Inc. announced that they will report Q2, 2025 results at 4:05 PM, US Eastern Standard Time on Aug 05, 2025 お知らせ • Jul 08
Cryoport's Mve Biological Solutions Introduces Next Generation Vapor Shippers Cryoport, Inc. announced the launch of MVE Biological Solutions' new vapor shippers, the SC 4/2V and SC 4/3V, offering medical and animal health professionals, laboratories, researchers, hospitals and clinics, pharmaceutical companies, and others dramatically improved safety and reliability for transporting and preserving sensitive biological materials at cryogenic temperatures. Built on MVE's legacy SC 4/2V and 4/3V vapor shipper platform, the next-generation SC 4/2V and4/3V models have been redesigned utilizing innovative technologies to offer customers added protection during extended or challenging shipments. These four-liter vapor shippers are engineered to safely transport critical biological materials such as cells and tissues materials for cell therapies, biopharma, reproductive health materials, and animal health materials, including vaccines, while maintaining the materials' integrity throughout the journey. The new SC 4/2V andSC 4/3V vapor shippers include several key advancements designed to enhance performance and reliability. Hold times for both next-generation models have been significantly extended to up to 19 days for the SC 4/2V (previously 13 days) and 26 days for the SC 4/3V (up from 21 days) which provides greater flexibility and security during transit delays. MVE's patented BEND DON'T BREAK™? technology features a specially designed top that flexes under stress, absorbing impact to reduce the risk of damage during rough handling that sometimes happens during shipping. Other upgraded features of the new vapor shippers include a newly integrated lid locking tab which helps prevent breakage, along with MVE's patent-pending Vapor Shield Technology, which minimizes the risk of vacuum loss caused by liquid nitrogen overfilling. These enhancements work together to provide greater reliability and " peace of mind" when transporting critical biological materials. お知らせ • May 08
Cryoport, Inc. Reiterates Revenue Guidance for Full Year Fiscal 2025 Cryoport, Inc. reiterated revenue guidance for full year fiscal 2025. The company is reiterating its revenue guidance for fiscal year 2025: total organic revenue is expected to be in the range of $165.0 million to $172.0 million, representing 5% to 10% growth year-over-year. The Company's 2025 guidance is dependent on its current business and expectations, which may be further impacted by, among other things, factors that are outside of control, such as national economic factors, the global macroeconomic and geopolitical environment, supply chain constraints, inflationary pressures, tariffs and other trade restrictions and/or the effects of foreign currency fluctuations, as well as the other factors described in the Company's filings with the Securities and Exchange Commission ("SEC"), including in the "Risk Factors" section of its most recently filed periodic reports on Form 10-K and Form 10-Q, as well as in its subsequent filings with the SEC. お知らせ • Apr 28
Cryoport, Inc., Annual General Meeting, Jun 06, 2025 Cryoport, Inc., Annual General Meeting, Jun 06, 2025. お知らせ • Apr 24
Cryoport, Inc. to Report Q1, 2025 Results on May 07, 2025 Cryoport, Inc. announced that they will report Q1, 2025 results After-Market on May 07, 2025 お知らせ • Apr 02
DHL Supply Chain International Holding B.V. entered into a Sale and Purchase Agreement to acquire Pdp Courier Services (Usa) Inc from Cryoport, Inc. (NasdaqCM:CYRX). DHL Supply Chain International Holding B.V. entered into a Sale and Purchase Agreement to acquire Pdp Courier Services (Usa) Inc from Cryoport, Inc. (NasdaqCM:CYRX) on March 31, 2025. In a related party transaction DHL Supply Chain International Holding B.V. also agreed to acquire Courier Polar Expres S.L., Advanced Therapy Logistics and Solutions, SAS and Cryo Express GmbH. for approximately $138 million in cash. The Transaction is expected to close in the second or third quarter of 2025 and is subject to customary closing conditions, including regulatory approval under relevant government antitrust and foreign direct investment laws. お知らせ • Mar 12
Cryoport's MVE Biological Solutions Expands High-Efficiency Cryogenic Freezer Series with Answer to Evolving Needs of Fertility Clinics, Biorepositories and Clinical Laboratories Cryoport, Inc. announced the launch of MVE Biological Solutions' High-Efficiency 800 C, the latest addition to its next-generation High-Efficiency ("HE") Series of cryogenic freezers. The HE 800 C combines ergonomic features and consistent performance in a compact size to meet the evolving needs of fertility clinics, biorepositories and clinical laboratories. Building on the trusted reputation of the HE Series, the HE 800 C provides ultra-low temperature storage at -190degC, ensuring the integrity of sensitive biological materials. The HE 800 C is compatible with SUC-1 inventory management systems, which enables easy identification and retrieval of samples to streamline sample organization and retrieval. Its superior ergonomic design makes loading and retrieving samples more accessible, reducing strain on laboratory personnel. お知らせ • Mar 05
Cryoport, Inc. Provides Revenue Guidance for the Year 2025 Cryoport, Inc. provided revenue guidance for the year 2025. For the year, the company expects revenue guidance in the range of $240 million - $250 million. The Company's 2025 guidance is dependent on its current business and expectations, which may be further impacted by, among other things, factors that are outside of control, such as national economic factors, the global macroeconomic and geopolitical environment, supply chain constraints, inflationary pressures, and/or the effects of foreign currency fluctuations, as well as the other factors described in the Company's filings with the Securities and Exchange Commission ("SEC"), including in the "Risk Factors" section of its most recently filed periodic reports on Form 10-K and Form 10-Q, as well as in its subsequent filings with the SEC. お知らせ • Feb 18
Cryoport, Inc. to Report Q4, 2024 Results on Mar 04, 2025 Cryoport, Inc. announced that they will report Q4, 2024 results at 4:05 PM, US Eastern Standard Time on Mar 04, 2025 お知らせ • Jan 22
Cryoport, Inc. Unveils Cryoport Express Cryogenic HV3 Shipping System Cryoport, Inc. unveiled its Cryoport Express Cryogenic HV3 Shipping System ("HV3"), the Company's newest product innovation in Cryoport's comprehensive portfolio of global end-to-end temperature-controlled supply chain offerings. The HV3 ensures unparalleled protection and accessibility for biologics and other temperature-sensitive materials. Its unique rectilinear design eliminates the need for palletization (securing goods on a pallet for transportation) and provides the ability to transport critical life science materials on narrow-bodied aircraft, ensuring compliance with regional carriers and reducing flight rejections and delays. As a result, the HV3 increases the number of available shipping lanes, which will improve patient access and enable life-saving therapies to reach patients in underserved areas. This newly developed shipping system offers enhanced payload protection and resilience during transport. With additional space for non-temperature sensitive accessories and documentation, the HV3 also improves storage efficiency through the ability to stack and nest the shippers, making it more cost-effective and user-friendly. Full compliance with airline requirements plus an integrated condition and location monitoring system provides full Chain of Compliance. Engineered to meet the specific needs of advanced therapies, the HV3 ensures enhanced payload security and superior temperature control, maintaining payload integrity and extended temperature stability at -150degC or lower. The HV3's structure also enhances mobility with its robust wheels and an integrated front-facing handle, improving accessibility at point-of-care sites. Its design also provides for scalability or higher density storage capabilities at manufacturing and clinical sites. While improving overall safety for clinicians and operators, these improvements enable more efficient handling (and storage) at point-of-care site, contract development and manufacturing organizations (CDMO's), and other storage locations, reducing the need for additional site-based resources. The HV3 is also designed to be used with Cryoport's Safepak System. The Safepak System is a purpose built solution that utilizes non-metallic, soft materials to minimize the effects of vibration and shock during the transport of cell and gene therapies. Reported Earnings • Nov 09
Third quarter 2024 earnings released: EPS: US$0.057 (vs US$0.31 loss in 3Q 2023) Third quarter 2024 results: EPS: US$0.057 (up from US$0.31 loss in 3Q 2023). Revenue: US$56.7m (flat on 3Q 2023). Net income: US$2.81m (up US$18.1m from 3Q 2023). Profit margin: 5.0% (up from net loss in 3Q 2023). Revenue is forecast to grow 7.5% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe. Reported Earnings • Aug 07
Second quarter 2024 earnings released: US$1.62 loss per share (vs US$0.42 loss in 2Q 2023) Second quarter 2024 results: US$1.62 loss per share (further deteriorated from US$0.42 loss in 2Q 2023). Revenue: US$57.6m (up 1.0% from 2Q 2023). Net loss: US$80.0m (loss widened 293% from 2Q 2023). Revenue is forecast to grow 8.8% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe. お知らせ • Jul 23
Cryoport, Inc. to Report Q2, 2024 Results on Aug 06, 2024 Cryoport, Inc. announced that they will report Q2, 2024 results After-Market on Aug 06, 2024 Recent Insider Transactions • May 17
Independent Lead Director recently sold €100k worth of stock On the 15th of May, Richard Jay Berman sold around 8k shares on-market at roughly €12.34 per share. This transaction amounted to 7.5% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of €271k more than they bought in the last 12 months. Reported Earnings • May 08
First quarter 2024 earnings released: US$0.34 loss per share (vs US$0.16 loss in 1Q 2023) First quarter 2024 results: US$0.34 loss per share (further deteriorated from US$0.16 loss in 1Q 2023). Revenue: US$54.6m (down 13% from 1Q 2023). Net loss: US$16.9m (loss widened 123% from 1Q 2023). Revenue is forecast to grow 9.8% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe. お知らせ • May 08
Cryoport, Inc. Reiterates Revenue Guidance for the Full Year 2024 Cryoport, Inc. reiterated revenue guidance for the full year 2024. The Company is reiterating its full year 2024 revenue guidance of $242 million to $252 million and continues to expect revenue to improve progressively throughout the year. New Risk • May 05
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 7.9% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$48m net loss in 3 years). Share price has been volatile over the past 3 months (9.0% average weekly change). Shareholders have been diluted in the past year (7.9% increase in shares outstanding). お知らせ • May 01
Cryoport, Inc. to Report Q1, 2024 Results on May 07, 2024 Cryoport, Inc. announced that they will report Q1, 2024 results at 4:05 PM, US Eastern Standard Time on May 07, 2024 お知らせ • Apr 04
Cryoport, Inc., Annual General Meeting, May 17, 2024 Cryoport, Inc., Annual General Meeting, May 17, 2024, at 10:00 Central Daylight. Agenda: To elect seven directors; to ratify the appointment of Deloitte & Touche LLP as the independent registered public accounting firm of the company and its subsidiaries for the year ending December 31, 2024; to approve, on an advisory basis, the compensation of the named executive officers, as disclosed in proxy statement for the Annual Meeting; to approve an amendment to the Cryoport, Inc. 2018 Omnibus Equity Incentive Plan to increase the number of authorized shares under the plan; and to transact such other business as may properly come before the meeting or any adjournment thereof. Board Change • Apr 01
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 7 highly experienced directors. Independent Director Linda Baddour was the last director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment. お知らせ • Mar 14
Cryoport, Inc. Announces Goodwill Impairment for the Quarter Ended December 31, 2023 Cryoport, Inc. announced goodwill impairment for the quarter ended December 31, 2023. For the quarter, the company reported Goodwill impairment of $49,569,000. お知らせ • Mar 13
Cryoport, Inc. Provides Revenue Guidance for the Year 2024 Cryoport, Inc. provided revenue guidance for the year 2024. The Company is expecting revenue to grow progressively and is providing full year 2024 revenue guidance of $242 million- $252 million. Reported Earnings • Mar 13
Full year 2023 earnings released: US$2.21 loss per share (vs US$0.93 loss in FY 2022) Full year 2023 results: US$2.21 loss per share (further deteriorated from US$0.93 loss in FY 2022). Revenue: US$233.3m (down 1.7% from FY 2022). Net loss: US$107.6m (loss widened 137% from FY 2022). Revenue is forecast to grow 9.0% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Life Sciences industry in Europe. お知らせ • Feb 28
Cryoport, Inc. to Report Q4, 2023 Results on Mar 12, 2024 Cryoport, Inc. announced that they will report Q4, 2023 results After-Market on Mar 12, 2024 お知らせ • Feb 16
Cryoport, Inc. Announces Transition of Edward Zecchini from the Board of Directors to Sr. Vice President - Chief Digital & Technology Officer On February 10, 2024, Edward Zecchini accepted the offer to join Cryoport, Inc. as Senior Vice President – Chief Digital & Technology Officer and submitted his resignation from the Board of Directors of the Company both effective February 19, 2024. There were no disagreements between Mr. Zecchini and the Company on any matter relating to the Company’s operations, policies or practices that led to his decision to resign. New Risk • Dec 06
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 9.4% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (9.4% average weekly change). Minor Risk Currently unprofitable and not forecast to become profitable over next 2 years (US$47m net loss in 2 years). お知らせ • Nov 17
Cryoport, Inc. (NasdaqCM:CYRX) acquired Bluebird Express LLC. Cryoport, Inc. (NasdaqCM:CYRX) acquired Bluebird Express LLC on November 16, 2023. Bluebird Express team of seasoned veterans will merge into CRYOPDP's global network and will expand U.S. presence.Cryoport, Inc. (NasdaqCM:CYRX) completed the acquisition of Bluebird Express LLC on November 16, 2023. お知らせ • Nov 10
Cryoport, Inc. Provides Revenue Guidance for the Year 2023 Cryoport, Inc. provided revenue guidance for the year 2023. The company expects full year 2023 revenue guidance range of $233 million to $243 million. Reported Earnings • Nov 09
Third quarter 2023 earnings released: US$0.31 loss per share (vs US$0.15 loss in 3Q 2022) Third quarter 2023 results: US$0.31 loss per share (further deteriorated from US$0.15 loss in 3Q 2022). Revenue: US$56.2m (down 7.1% from 3Q 2022). Net loss: US$15.3m (loss widened 109% from 3Q 2022). Revenue is forecast to grow 10% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe. お知らせ • Nov 03
Cryoport, Inc. (NasdaqCM:CYRX) acquired Tec4Med Lifescience GmbH. Cryoport, Inc. (NasdaqCM:CYRX) acquired Tec4Med Lifescience GmbH on November 2, 2023.Cryoport, Inc. (NasdaqCM:CYRX) completed the acquisition of Tec4Med Lifescience GmbH on November 2, 2023. お知らせ • Oct 26
Cryoport, Inc. to Report Q3, 2023 Results on Nov 08, 2023 Cryoport, Inc. announced that they will report Q3, 2023 results at 4:05 PM, US Eastern Standard Time on Nov 08, 2023 Reported Earnings • Aug 10
Second quarter 2023 earnings released: US$0.42 loss per share (vs US$0.23 loss in 2Q 2022) Second quarter 2023 results: US$0.42 loss per share (further deteriorated from US$0.23 loss in 2Q 2022). Revenue: US$57.0m (down 11% from 2Q 2022). Net loss: US$20.4m (loss widened 82% from 2Q 2022). Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Life Sciences industry in Europe. お知らせ • Aug 03
Cryoport, Inc. to Report Q2, 2023 Results on Aug 09, 2023 Cryoport, Inc. announced that they will report Q2, 2023 results at 4:05 PM, US Eastern Standard Time on Aug 09, 2023 New Risk • Jul 14
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (12% average weekly change). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (US$18m net loss in 2 years). Significant insider selling over the past 3 months (€142k sold). お知らせ • Jul 13
Cryoport, Inc. Provides Earnings Guidance for the Second Quarter and Full Year 2023 Cryoport, Inc. provided earnings guidance for the second quarter and full year 2023. For the quarter, total revenue is expected to be in the range of $56.5 Million to $57.5 Million, representing a decrease of 11%, at the midpoint, compared to the second quarter of 2022. For the year, the Company is revising its full year financial outlook, with revenue now expected to be in the range of $233 Million to $243 Million. Recent Insider Transactions • May 15
Independent Lead Director recently sold €142k worth of stock On the 11th of May, Richard Jay Berman sold around 7k shares on-market at roughly €19.70 per share. This transaction amounted to 6.7% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of €575k more than they bought in the last 12 months. Reported Earnings • May 05
First quarter 2023 earnings released: US$0.16 loss per share (vs US$0.31 loss in 1Q 2022) First quarter 2023 results: US$0.16 loss per share (improved from US$0.31 loss in 1Q 2022). Revenue: US$62.8m (up 20% from 1Q 2022). Net loss: US$7.57m (loss narrowed 51% from 1Q 2022). お知らせ • May 05
Cryoport, Inc. Provides Revenue Guidance for the Year 2023 Cryoport, Inc. provided revenue guidance for the year 2023. The company's revenue guidance of $270 million - $290 million for the full year 2023 is expected to be driven largely by ongoing support of global clinical trials, a growing number of commercial cell and gene therapy products from clients, the expansion of cell and gene manufacturing capacity to meet patient demand, and the demand for biostorage and cryogenic freezer systems. The company's 2023 guidance also assumes the launch of new services and products, designed to further expand, and strengthen industry position. Recent Insider Transactions • Mar 19
Chairman recently sold €51k worth of stock On the 15th of March, Jerrell Shelton sold around 3k shares on-market at roughly €19.73 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was Jerrell's only on-market trade for the last 12 months. Breakeven Date Change • Feb 26
No longer forecast to breakeven The 9 analysts covering Cryoport no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$7.70m in 2025. New consensus forecast suggests the company will make a loss of US$2.40m in 2025. お知らせ • Feb 16
Cryoport, Inc. to Report Q4, 2022 Results on Feb 23, 2023 Cryoport, Inc. announced that they will report Q4, 2022 results at 4:05 PM, US Eastern Standard Time on Feb 23, 2023 Breakeven Date Change • Dec 31
Forecast to breakeven in 2025 The 9 analysts covering Cryoport expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of US$7.70m in 2025. Average annual earnings growth of 40% is required to achieve expected profit on schedule. Recent Insider Transactions • Dec 06
Independent Lead Director recently sold €136k worth of stock On the 1st of December, Richard Jay Berman sold around 7k shares on-market at roughly €18.70 per share. This transaction amounted to 6.8% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of €334k more than they bought in the last 12 months. Reported Earnings • Nov 05
Third quarter 2022 earnings released: US$0.15 loss per share (vs US$0.18 loss in 3Q 2021) Third quarter 2022 results: US$0.15 loss per share (improved from US$0.18 loss in 3Q 2021). Revenue: US$60.5m (up 6.7% from 3Q 2021). Net loss: US$7.32m (loss narrowed 14% from 3Q 2021). Revenue is forecast to grow 18% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe. お知らせ • Nov 04
Cryoport, Inc. Revises Revenue Guidance for the Year 2022 Cryoport, Inc. revised revenue guidance for the year 2022. The company's revised revenue guidance for the full year 2022 is $232 million - $238 million, and will be driven primarily by the growth from support of global clinical trials and commercially launched therapies from cell and gene therapy clients; growth in temperature-controlled logistics for the life sciences industry; and demand for cryogenic systems solutions. お知らせ • Oct 28
Cryoport, Inc. to Report Q3, 2022 Results on Nov 03, 2022 Cryoport, Inc. announced that they will report Q3, 2022 results at 4:00 PM, US Eastern Standard Time on Nov 03, 2022 Recent Insider Transactions • Aug 18
Independent Lead Director recently sold €115k worth of stock On the 16th of August, Richard Jay Berman sold around 3k shares on-market at roughly €42.31 per share. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of €198k more than they bought in the last 12 months. Reported Earnings • Aug 05
Second quarter 2022 earnings released: US$0.15 loss per share (vs US$0.16 loss in 2Q 2021) Second quarter 2022 results: US$0.15 loss per share (up from US$0.16 loss in 2Q 2021). Revenue: US$64.2m (up 14% from 2Q 2021). Net loss: US$7.18m (loss narrowed 2.9% from 2Q 2021). Over the next year, revenue is forecast to grow 21%, compared to a 7.2% growth forecast for the industry in Germany. お知らせ • Jul 29
Cryoport, Inc. to Report Q2, 2022 Results on Aug 04, 2022 Cryoport, Inc. announced that they will report Q2, 2022 results After-Market on Aug 04, 2022 Breakeven Date Change • Jun 13
Forecast to breakeven in 2024 The 9 analysts covering Cryoport expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 84% per year to 2023. The company is expected to make a profit of US$5.75m in 2024. Average annual earnings growth of 68% is required to achieve expected profit on schedule.